$136.33
1.02% yesterday
Nasdaq, Dec 20, 09:46 pm CET
ISIN
US04351P1012
Symbol
ASND
Sector
Industry

Ascendis Pharma A/S Sponsored ADR Stock price

$136.38
+12.00 9.65% 1M
+14.76 12.14% 6M
+10.43 8.28% YTD
+15.22 12.56% 1Y
+1.99 1.48% 3Y
+9.38 7.39% 5Y
+117.55 624.27% 10Y
Nasdaq, Closing price Fri, Dec 20 2024
-1.36 0.99%
ISIN
US04351P1012
Symbol
ASND
Sector
Industry

Key metrics

Market capitalization $8.15b
Enterprise Value $8.33b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 23.51
P/S ratio (TTM) P/S ratio 22.99
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 117.15%
Revenue (TTM) Revenue $354.45m
EBIT (operating result TTM) EBIT $-342.44m
Free Cash Flow (TTM) Free Cash Flow $-277.97m
Cash position $698.11m
EPS (TTM) EPS $-8.10
P/E forward negative
P/S forward 26.39
EV/Sales forward 26.98
Short interest 8.03%
Show more

Is Ascendis Pharma A/S Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.

Ascendis Pharma A/S Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast:

14x Buy
100%

Analyst Opinions

14 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast:

Buy
100%

Financial data from Ascendis Pharma A/S Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
354 354
117% 117%
100%
- Direct Costs 69 69
46% 46%
19%
285 285
146% 146%
81%
- Selling and Administrative Expenses 269 269
12% 12%
76%
- Research and Development Expense 339 339
26% 26%
96%
-323 -323
45% 45%
-91%
- Depreciation and Amortization 20 20
0% 0%
6%
EBIT (Operating Income) EBIT -342 -342
43% 43%
-97%
Net Profit -462 -462
28% 28%
-130%

In millions USD.

Don't miss a Thing! We will send you all news about Ascendis Pharma A/S Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ascendis Pharma A/S Sponsored ADR Stock News

Neutral
GlobeNewsWire
2 days ago
COPENHAGEN, Denmark, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide; developed as TransCon PTH) is now commercially available by prescription in the United States. YORVIPATH is a prodrug of parathyroid hormone (PTH [1-34]), administered once-daily, designed to provide continuous exposure to active PTH over the 24-hour do...
Neutral
GlobeNewsWire
5 days ago
- Results for all three TransCon hGH starting dose cohorts, in first clinical trial of an indication outside of growth hormone deficiency, showed a safety and tolerability profile comparable to daily somatropin
Neutral
GlobeNewsWire
9 days ago
COPENHAGEN, Denmark, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) in adult growth hormone deficiency (GHD) for TransCon hGH (lonapegsomatropin-tcgd; marketed as SKYTROFA® for pediatric GHD). The FDA set a Prescription Drug User Fee ...
More Ascendis Pharma A/S Sponsored ADR News

Company Profile

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.

Head office Denmark
CEO Jan Mikkelsen
Founded 2006
Website www.ascendispharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today